2019
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement
Sears CR, Peikert T, Possick JD, Naidoo J, Nishino M, Patel SP, Camus P, Gaga M, Garon EB, Gould MK, Limper AH, Montgrain PR, Travis WD, Rivera MP. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal Of Respiratory And Critical Care Medicine 2019, 200: e31-e43. PMID: 31518182, PMCID: PMC6775885, DOI: 10.1164/rccm.201906-1202st.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsICI-pneumonitisCheckpoint inhibitorsOfficial American Thoracic Society Research StatementUse of ICIsLife-threatening pneumonitisUnique adverse eventsBiological mechanismsAdverse eventsRadiologic featuresRadiologic presentationCancer careBiologic mechanismsResearch prioritiesBasic biological mechanismsMultidisciplinary groupPneumonitisClinical researchersDiagnosisInhibitorsPrecipitous increaseTherapyAvailable dataCare
2018
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rateBiomarkers as Common Data Elements for Symptom and Self‐Management Science
Page GG, Corwin EJ, Dorsey SG, Redeker NS, McCloskey DJ, Austin JK, Guthrie BJ, Moore SM, Barton D, Kim MT, Docherty SL, Waldrop‐Valverde D, Bailey DE, Schiffman RF, Starkweather A, Ward TM, Bakken S, Hickey KT, Renn CL, Grady P. Biomarkers as Common Data Elements for Symptom and Self‐Management Science. Journal Of Nursing Scholarship 2018, 50: 276-286. PMID: 29575635, PMCID: PMC5945303, DOI: 10.1111/jnu.12378.Peer-Reviewed Original ResearchConceptsCommon data elementsSelf-management scienceBrain-derived neurotrophic factorAnti-inflammatory cytokinesAddition of biomarkersMechanisms of symptomsAdrenal axis markersSymptom scienceNeurotrophic factorChronic conditionsSymptom experienceBiologic mechanismsBehavioral symptomsSymptomsSymptom researchSymptom InventoryTreatment effortsBiomarkers
2017
Multiparameter Single Cell Profiling of Airway Inflammatory Cells
Yao Y, Welp T, Liu Q, Niu N, Wang X, Britto CJ, Krishnaswamy S, Chupp G, Montgomery RR. Multiparameter Single Cell Profiling of Airway Inflammatory Cells. Cytometry Part B Clinical Cytometry 2017, 92: 12-20. PMID: 27807928, PMCID: PMC5250532, DOI: 10.1002/cyto.b.21491.Peer-Reviewed Original ResearchConceptsSingle-cell methodsComplex trait diseasesSubgroup of asthmaticsSingle-cell analysisMultiparameter single cell analysisMillions of patientsTranscriptional analysisImmunologic underpinningsInduced sputumAirway diseaseAsthmatic patientsAirway samplesCell subsetsImmune statusFunctional statusClinical severityDistinct biologic mechanismsTreatment successPhysiologic manifestationsBiologic mechanismsCystic fibrosisCellular analysisPatientsCytometry studiesU.S. population
2016
Associations of Preimplant Red Blood Cell Distribution Width with Clinical Outcomes Among Individuals with Left Ventricular Assist Devices
Miller PE, Houston BA, Schneider AL, Bush AL, Whitman GJ, Stevens GR, Tedford RJ, Russell SD. Associations of Preimplant Red Blood Cell Distribution Width with Clinical Outcomes Among Individuals with Left Ventricular Assist Devices. ASAIO Journal 2016, 62: 677-683. PMID: 27798492, DOI: 10.1097/mat.0000000000000431.Peer-Reviewed Original ResearchConceptsRed blood cell distribution widthCell distribution widthVentricular assist deviceHeart failureClinical outcomesAssist deviceEnd-stage heart failureDistribution widthPost-LVAD complicationsContinuous-flow LVADProportional hazards modelPostimplant mortalityRDW tertilesGastrointestinal bleedAdverse eventsSecondary outcomesLaboratory variablesLVAD populationFull adjustmentPrognostic abilityHigh riskHazards modelBiologic mechanismsMortalityTertile
2015
Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers
Esterhuyse M, Weiner J, Caron E, Loxton A, Iannaccone M, Wagman C, Saikali P, Stanley K, Wolski W, Mollenkopf H, Schick M, Aebersold R, Linhart H, Walzl G, Kaufmann S. Epigenetics and Proteomics Join Transcriptomics in the Quest for Tuberculosis Biomarkers. MBio 2015, 6: 10.1128/mbio.01187-15. PMID: 26374119, PMCID: PMC4600108, DOI: 10.1128/mbio.01187-15.Peer-Reviewed Original ResearchConceptsTB patientsPilot studyActive tuberculosis diseaseLarge-scale studiesSpread of TBLTBI controlLTBI participantsTuberculosis infectionTuberculosis diseaseDisease progressionHealthy controlsPrognostic biomarkerImmune responseBiologic mechanismsHealthy individualsPatientsHost responseInfected individualsBetter careInfectious diseasesMycobacterium tuberculosisSmall sample sizeBiomarker developmentRegulation of functionDNA methylationRace, Ethnicity, and Socioeconomic Status in Research on Child Health
Cheng T, Goodman E, Cheng T, Bogue C, Chien A, Dean J, Kharbanda A, Peeples E, Scheindlin B. Race, Ethnicity, and Socioeconomic Status in Research on Child Health. 2015, 135: e225-e237. PMID: 25548336, PMCID: PMC9923597, DOI: 10.1542/peds.2014-3109.Peer-Reviewed Original ResearchConceptsChild healthHealth care disparitiesSocioeconomic statusCare disparitiesHealth care outcomesAdult morbidityPotential confoundingCare outcomesBiologic mechanismsHealth outcomesAmerican AcademyLife courseHealth careAdolescent HealthMorbidityOutcomesHealthBiologic influencesEthnicityExtensive literature documentsMore researchAAPDisparitiesMisattribution of causalityStatus
2011
Will preoperative trials change future clinical practice?
Lim E, Winer E. Will preoperative trials change future clinical practice? Clinical Investigation 2011, 1: 59-73. DOI: 10.4155/cli.10.3.Peer-Reviewed Original ResearchPreoperative systemic therapySystemic therapyBreast cancerOperable breast cancerManagement of patientsPST trialsPost-treatment tissuesFuture clinical practiceAdjuvant trialsBreast cancePredictive biomarkersPreoperative trialBiomarker discovery programsBiologic mechanismsClinical practiceTherapyVivo studiesTrialsOff-target effectsIdentification of pathwaysCorrelative studiesDrug developmentCancerPatientsDiscovery programs
2001
Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin
Herbst R, Lee A, Tran H, Abbruzzese J. Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. Current Oncology Reports 2001, 3: 131-140. PMID: 11177745, DOI: 10.1007/s11912-001-0013-8.Peer-Reviewed Original ResearchConceptsPhase I trialI trialClinical studiesHuman endostatinTumor vasculatureSolid tumor malignanciesAnti-angiogenic agentsAnti-angiogenic mechanismAnti-angiogenic compoundsToxic cancer treatmentsAdvanced diseaseBlood vessel supplyCenter trialMinimal diseaseTumor sizeNovel agentsSurrogate endpointsNew agentsSide effectsBiologic mechanismsSingle agentAngiogenesis inhibitorsGrowth-inhibiting moleculesNon-toxic agentsTumor growth
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply